Related Experiment Video
Updated: Jan 23, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
MicroRNA-378 attenuates myocardial fibrosis by inhibiting MAPK/ERK pathway
1Department of Cardiovascular Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China. spfsunny@126.com.
Objective:
To elucidate the role of microRNA-378-containing microvesicles (MVs) in the process of myocardial fibrosis and its underlying mechanism.
Materials And Methods:
In vivo chronic myocardial fibrosis (MF) model in rats was established by aortic coarctation method. MicroRNA-378 mimic or inhibitor was injected into the rat tail vein at day 3 after the aortic coarctation. Two weeks later, rats were sacrificed for collecting myocardium. MVs were isolated from rat cardiomyocytes and further verified by detecting the expression level of its marker CD63. Expression levels of fibrosis-related indicators and microRNA-378 in MVs were determined by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) and Western blot. After induction with transforming growth factor-β1 (TGF-β1) in primary rat cardiomyocytes for different time points, expression levels of fibrosis-related indicators and microRNA-378 were also accessed. Changes in mitogen-activated protein kinase (MAPK) pathway were observed during the process of MF by qRT-PCR and Western blot.
Results:
Expression levels of microRNA-378-containing MVs decreased, and the MAPK pathway was activated during the process of MF, which further aggravated MF.
Conclusions:
MicroRNA-378-containing MVs alleviate myocardial fibrosis through inhibiting the phosphorylation of MAPK.
Insights
MicroRNA-378-containing microvesicles (MVs) alleviate myocardial fibrosis by inhibiting the MAPK pathway. Reduced MV levels worsen fibrosis, highlighting their protective role.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Biochemistry
Background:
- Myocardial fibrosis (MF) is a pathological process contributing to heart dysfunction.
- Microvesicles (MVs) are emerging as key mediators in intercellular communication.
- MicroRNA-378's role in cardiovascular disease requires further elucidation.
Purpose of the Study:
- To investigate the function of microRNA-378-containing microvesicles (MVs) in myocardial fibrosis.
- To explore the underlying molecular mechanisms involving the mitogen-activated protein kinase (MAPK) pathway.
Main Methods:
- Established a rat model of chronic myocardial fibrosis via aortic coarctation.
- Administered microRNA-378 mimics or inhibitors and isolated MVs from cardiomyocytes.
- Quantified fibrosis indicators, microRNA-378, and MAPK pathway activation using qRT-PCR and Western blot.
Main Results:
- Decreased levels of microRNA-378-containing MVs were observed in the myocardial fibrosis model.
- Activation of the MAPK pathway correlated with increased myocardial fibrosis.
- MicroRNA-378-containing MVs were found to inhibit MAPK phosphorylation.
Conclusions:
- MicroRNA-378-containing MVs play a protective role against myocardial fibrosis.
- These MVs exert their effect by suppressing the phosphorylation of the MAPK pathway.
- Targeting microRNA-378-containing MVs may offer a therapeutic strategy for myocardial fibrosis.
Related Concept Videos
MicroRNAs
MicroRNAs
Feedback Inhibition
Transcription Attenuation in Prokaryotes
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
MAPK Signaling Cascades
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...

